Comparison of Growth Patterns of Acute Myeloid Leukemia Cells In Vitro and In Vivo by Flow Cytometry

Author(s):  
R. Nowak ◽  
U. Oelschägel ◽  
R. Hofmann ◽  
M. Palitzsch ◽  
H. Zengler ◽  
...  
Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2846-2846 ◽  
Author(s):  
Nan-Nan Zhang ◽  
Lei Chen ◽  
Wu Zhang ◽  
Xian-Yang Li ◽  
Lin-Jia Jiang ◽  
...  

Abstract Acute promyelocytic leukemia (APL) is initiated by the formation of PML/RARα oncogenic fusion protein, a potent transcriptional repressor. Retinoid acid (RA) at pharmacological dosage can physically bind to the PML/RARα protein, ushering in the unfolding of downstream programs normally regulated by the wild type RARα. However, through what particular regulatory pathways RA inhibits APL malignant hematopoiesis has remained largely obscured. Rig-I is one of the genes whose mRNA levels were highly up-regulated, along with all-trans-RA (ATRA)-induced terminal granulocytic differentiation of APL cell line NB4 cells in vitro. Based on the analysis of a Rig-I−/− mouse model, recently we have reported a critical regulatory role of Rig-I in normal granulopoiesis. To understand the functional contribution of Rig-I induction in RA-mediated leukemia cell differentiation, we converted a pair of previously reported Rig-I RNAi-duplex sequences into a miR30a-based small hairpin-encoding sequence, which was expressed under the CMV enhancer/promoter within a lentiviral vector. As expected, Rig-I shRNAmir30 infection induced a significant knockdown of Rig-I protein level, and accordingly its delivery into HL-60 cells partially inhibited ATRA-induced granulocytic differentiation, growth inhibition/cell cycle arrest and apoptosis induction, suggesting that Rig-I upregulation participates in RA-induced granulocytic differentiation of acute myeloid leukemia cells. In order to investigate the effect of Rig-I induction on the proliferation of APL cells in vivo, we transduced PML/RARα-harboring leukemic cells with vector or Rig-I-expressing retrovirus, and then transplanted these cells into the syngeneic mice. The vector-transduced APL cells readily expanded in vivo, but the proliferation of Rig-I-transduced cells was apparently prohibited. Moreover, we found that the forced expression of Rig-I induced the expression of numerous ISGs in APL cells, which was recapitulated by the transduction of the C terminal part of Rig-I, but not by the N terminal part. In line with this, during the in vitro short-term culture post-IFNγ or IFNα stimulation, Stat1 phosphorylation at p701 in Rig-I−/− granulocytes was significantly inhibited. In parallel, the induction of multiple ISGs by IFNs was also significantly impaired. In conclusion, our findings indicate that the Rig-I induction inhibited APL reconstitution potentially through up-regulating a number of ISGs via regulating Stat1Tyr701 phosphorylation.


Blood ◽  
2015 ◽  
Vol 125 (26) ◽  
pp. 4060-4068 ◽  
Author(s):  
Farideh Miraki-Moud ◽  
Essam Ghazaly ◽  
Linda Ariza-McNaughton ◽  
Katharine A. Hodby ◽  
Andrew Clear ◽  
...  

Key Points Most AMLs lack ASS1, which allows synthesis of arginine, and so depend on exogenous sources. Depletion of arginine via ADI-PEG 20 reduces the burden of primary AML in vivo and in vitro.


2016 ◽  
Author(s):  
Laura M. Bystrom ◽  
Luis Andres Lara-Martinez ◽  
Bernardo Gomel ◽  
Burak Isal ◽  
Hongliang Zong ◽  
...  

Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
LM Bystrom ◽  
H Zong ◽  
LAL Martinez ◽  
C Neto ◽  
GJ Roboz ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (3) ◽  
pp. 410-414 ◽  
Author(s):  
Ewa M. Kosciuczuk ◽  
Diana Saleiro ◽  
Barbara Kroczynska ◽  
Elspeth M. Beauchamp ◽  
Frank Eckerdt ◽  
...  

Key Points Merestinib blocks Mnk kinase activity in acute myeloid leukemia cells. Merestinib suppresses human leukemic progenitors and exhibits potent antileukemic effects in a xenograft mouse model.


Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1725 ◽  
Author(s):  
Nizar Serhan ◽  
Pierre-Luc Mouchel ◽  
Philippe de Medina ◽  
Gregory Segala ◽  
Aurélie Mougel ◽  
...  

Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the inhibition of a sterol isomerase. We hypothesize that DDA could potentiate the activity of an anticancer drug acting through a different molecular mechanism, and conducted in vitro and in vivo combination tests on AML cell lines and patient primary tumors. We report here results from tests combining DDA with antimetabolite cytarabine (Ara-C), one of the main drugs used for AML treatment worldwide. We demonstrated that DDA potentiated and sensitized AML cells, including primary patient samples, to Ara-C in vitro and in vivo. Mechanistic studies revealed that this sensitization was LXRβ-dependent and was due to the activation of lethal autophagy. This study demonstrates a positive in vitro and in vivo interaction between DDA and Ara-C, and supports the clinical evaluation of DDA in combination with Ara-C for the treatment of AML.


Sign in / Sign up

Export Citation Format

Share Document